{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T15:11:48Z","timestamp":1785510708865,"version":"3.56.0"},"reference-count":177,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009104","name":"Department of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009104","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.prp.2026.156471","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T05:01:02Z","timestamp":1776142862000},"page":"156471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Glioblastoma IDH-wildtype: An integrative review of pathophysiological mechanisms, diagnostic innovations, and emerging therapeutic modalities"],"prefix":"10.1016","volume":"282","author":[{"given":"Pranav","family":"Dhingra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghanshyam","family":"Das Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balak","family":"Das Kurmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2026.156471_bib1","doi-asserted-by":"crossref","first-page":"12870","DOI":"10.1109\/ACCESS.2023.3242666","article-title":"Brain tumor detection and classification using intelligence techniques: an overview","volume":"11","author":"Solanki","year":"2023","journal-title":"IEEE Access"},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12880-024-01195-7","article-title":"A hybrid deep CNN model for brain tumor image multi-classification","volume":"24","author":"Srinivasan","year":"2024","journal-title":"BMC Med. Imaging"},{"key":"10.1016\/j.prp.2026.156471_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1255611","article-title":"Immunotherapy: a promising approach for glioma treatment","volume":"14","author":"Yasinjan","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156471_bib4","article-title":"Contralateral neurofluid dynamics predict survival in IDH wild-type glioblastoma: a DTI-ALPS and free water imaging study","author":"Hagiwara","year":"2025","journal-title":"Neuro-Oncology"},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/bpa.70035","article-title":"cIMPACT-NOW update 11: proposal on adaptation of diagnostic criteria for IDH- and H3-wildtype diffuse high-grade gliomas and for posterior fossa ependymal tumors","volume":"36","author":"Wesseling","year":"2026","journal-title":"Brain Pathol."},{"issue":"5","key":"10.1016\/j.prp.2026.156471_bib6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1159\/000531319","article-title":"Glioblastoma multiforme: the latest diagnostics and treatment techniques","volume":"108","author":"Czarnywojtek","year":"2023","journal-title":"Pharmacology"},{"issue":"7","key":"10.1016\/j.prp.2026.156471_bib7","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s12032-025-02830-1","article-title":"Unlocking glioblastoma: breakthroughs in molecular mechanisms and next-generation therapies","volume":"42","author":"Rizwani","year":"2025","journal-title":"Med Oncol."},{"issue":"3","key":"10.1016\/j.prp.2026.156471_bib8","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11060-025-04944-y","article-title":"Cancers of the brain and central nervous system: global patterns and trends in incidence","volume":"172","author":"Filho","year":"2025","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.prp.2026.156471_bib9","first-page":"3","article-title":"Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment","volume":"18","author":"Hanif","year":"2017","journal-title":"Asian Pac. J. Cancer Prevent. APJCP"},{"key":"10.1016\/j.prp.2026.156471_bib10","article-title":"Glioblastoma: clinical presentation, diagnosis, and management","volume":"374","author":"McKinnon","year":"2021","journal-title":"Bmj"},{"issue":"10","key":"10.1016\/j.prp.2026.156471_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14102412","article-title":"Epidemiology of glioblastoma multiforme-literature review","volume":"14","author":"Grochans","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2026.156471_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7897\/2230-8407.0912283","article-title":"Glioblastoma multiforme: a review of its pathogenesis and treatment","volume":"9","author":"Banu","year":"2019","journal-title":"Int. Res. J. Pharm."},{"key":"10.1016\/j.prp.2026.156471_bib13","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/pore.2024.1611549","article-title":"Extracellular vesicles as modulators of glioblastoma progression and tumor microenvironment","volume":"30","author":"Dai","year":"2024","journal-title":"Pathol. Oncol. Res."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib14","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12935-025-03721-1","article-title":"Amino acid metabolism in glioblastoma pathogenesis, immune evasion, and treatment resistance","volume":"25","author":"Srivastava","year":"2025","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.prp.2026.156471_bib15","doi-asserted-by":"crossref","unstructured":"Ren, R., Z. Li, and Q. Fang, A disintegrin-like and metalloproteinase 15 facilitates glioblastoma proliferation and metastasis through activation of the protease-activated receptor 1. Cytojournal. 22: p. 34.","DOI":"10.25259\/Cytojournal_92_2024"},{"issue":"8","key":"10.1016\/j.prp.2026.156471_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13081882","article-title":"Glioblastoma: a multidisciplinary approach to its pathophysiology, treatment, and innovative therapeutic strategies","volume":"13","author":"Esparza-Salazar","year":"2025","journal-title":"Biomedicines"},{"issue":"20","key":"10.1016\/j.prp.2026.156471_bib17","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1158\/1078-0432.CCR-24-1563","article-title":"Remote neuroinflammation in newly diagnosed glioblastoma correlates with unfavorable clinical outcome","volume":"30","author":"Bartos","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.prp.2026.156471_bib18","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14489","article-title":"A TGF-\u03b2 signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response","volume":"30","author":"Duan","year":"2024","journal-title":"CNS Neurosci. Ther."},{"issue":"5","key":"10.1016\/j.prp.2026.156471_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052607","article-title":"Molecular pathogenesis of glioblastoma in adults and future perspectives: a systematic review","volume":"23","author":"Esemen","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.prp.2026.156471_bib20","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.3390\/ijms25053040","article-title":"Glioblastoma: an update in pathology, molecular mechanisms and biomarkers","volume":"25","author":"Lan","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12957-022-02602-5","article-title":"Tracing the origins of glioblastoma by investigating the role of gliogenic and related neurogenic genes\/signaling pathways in GBM development: a systematic review","volume":"20","author":"Shafi","year":"2022","journal-title":"World J. Surg. Oncol."},{"issue":"4","key":"10.1016\/j.prp.2026.156471_bib22","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.3390\/ijms22041831","article-title":"Receptor tyrosine kinase signaling and targeting in glioblastoma multiforme","volume":"22","author":"Tilak","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.prp.2026.156471_bib23","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3892\/ol.2025.14989","article-title":"Key genes altered in glioblastoma based on bioinformatics (Review)","volume":"29","author":"Al Ghafari","year":"2025","journal-title":"Oncol. Lett."},{"issue":"9","key":"10.1016\/j.prp.2026.156471_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10090297","article-title":"The p53 pathway in glioblastoma","volume":"10","author":"Zhang","year":"2018","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.prp.2026.156471_bib25","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/jnen\/nlab109","article-title":"Alterations in the RB pathway with inactivation of RB1 characterize glioblastomas with a primitive neuronal component","volume":"80","author":"Chkheidze","year":"2021","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"5","key":"10.1016\/j.prp.2026.156471_bib26","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3390\/cancers13051147","article-title":"TERT promoter alterations in glioblastoma: a systematic review","volume":"13","author":"Olympios","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.prp.2026.156471_bib27","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s00432-021-03536-3","article-title":"Human TERT promoter mutations as a prognostic biomarker in glioma","volume":"147","author":"Powter","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12883-024-03605-3","article-title":"A systematic review of high impact CpG sites and regions for MGMT methylation in glioblastoma [A systematic review of MGMT methylation in GBM]","volume":"24","author":"Gibson","year":"2024","journal-title":"BMC Neurol."},{"issue":"12","key":"10.1016\/j.prp.2026.156471_bib29","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.3390\/cells12121639","article-title":"Association between MGMT enhancer methylation and MGMT promoter methylation, MGMT protein expression, and overall survival in glioblastoma","volume":"12","author":"Zappe","year":"2023","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.prp.2026.156471_bib30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.14744\/ejmo.2024.54846","article-title":"Mps1 knockdown in glioblastoma induces DNA damage and up regulation of histone methyltransferase SETD2.","volume":"8","author":"Jema\u00e0","year":"2024","journal-title":"Eurasia J. Med. Oncol."},{"issue":"4","key":"10.1016\/j.prp.2026.156471_bib31","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41401-021-00679-4","article-title":"Role of TRPM2 in brain tumours and potential as a drug target","volume":"43","author":"Ji","year":"2022","journal-title":"Acta Pharm. Sin."},{"issue":"19","key":"10.1016\/j.prp.2026.156471_bib32","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.3390\/cancers17193176","article-title":"Challenges and opportunities in high-grade glioma management and imaging-based response monitoring during novel immunotherapies","volume":"17","author":"Gallegos","year":"2025","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib33","article-title":"Standard clinical approaches and emerging modalities for glioblastoma imaging","volume":"4","author":"Bernstock","year":"2022","journal-title":"Neuro-Oncol. Adv."},{"issue":"11","key":"10.1016\/j.prp.2026.156471_bib34","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.2009.26.3541","article-title":"Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group","volume":"28","author":"Wen","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.prp.2026.156471_bib35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11912-021-01020-2","article-title":"Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors","volume":"23","author":"Overcast","year":"2021","journal-title":"Curr. Oncol. Rep."},{"issue":"8","key":"10.1016\/j.prp.2026.156471_bib36","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"issue":"7","key":"10.1016\/j.prp.2026.156471_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics15070896","article-title":"The value of cerebral blood volume derived from dynamic susceptibility contrast perfusion MRI in predicting IDH mutation status of brain gliomas-a systematic review and meta-analysis","volume":"15","author":"Mart\u00ednez Barbero","year":"2025","journal-title":"Diagnostics"},{"issue":"5","key":"10.1016\/j.prp.2026.156471_bib38","first-page":"5418","article-title":"Quantitative analysis of permeability for glioma grading using dynamic contrast\u2011enhanced magnetic resonance imaging","volume":"14","author":"Zhao","year":"2017","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.prp.2026.156471_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030618","article-title":"Diffusion weighted imaging in neuro-oncology: diagnosis, post-treatment changes, and advanced sequences-an updated review","volume":"15","author":"Romano","year":"2023","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.prp.2026.156471_bib40","article-title":"Glioblastoma: overview and magnetic resonance spectroscopy analysis for treatment","volume":"16","author":"Syed","year":"2024","journal-title":"Cureus"},{"issue":"6","key":"10.1016\/j.prp.2026.156471_bib41","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/neuonc\/noab013","article-title":"Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET\/RANO group","volume":"23","author":"Galldiks","year":"2021","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1021\/acs.bioconjchem.5c00527","article-title":"Multivoid magnetic nanoparticles as high-performance magnetic particle imaging tracers for precise glioma detection","volume":"37","author":"Liang","year":"2026","journal-title":"Bioconjugate Chem."},{"issue":"2","key":"10.1016\/j.prp.2026.156471_bib43","first-page":"281","article-title":"Perfusion MRI-based differentiation between early tumor progression and pseudoprogression in glioblastoma and its use in clinical practice","volume":"12","author":"van Dorth","year":"2025","journal-title":"Neurooncol. Pr."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib44","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/neuonc\/noad189","article-title":"RANO 2.0: the revised response assessment in neuro-oncology (RANO) criteria for high- and low-grade glial tumors in adults designed for the future","volume":"26","author":"Wen","year":"2024","journal-title":"Neuro Oncol."},{"issue":"8","key":"10.1016\/j.prp.2026.156471_bib45","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/neuonc\/noab120","article-title":"The 2021 WHO classification of tumors of the central nervous system: clinical implications","volume":"23","author":"Wen","year":"2021","journal-title":"Neuro Oncol."},{"issue":"9","key":"10.1016\/j.prp.2026.156471_bib46","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1093\/neuonc\/noab105","article-title":"MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a cochrane systematic review","volume":"23","author":"Brandner","year":"2021","journal-title":"Neuro Oncol."},{"issue":"5","key":"10.1016\/j.prp.2026.156471_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17050744","article-title":"Clinical impact of a next-generation sequencing approach for glioblastoma patients","volume":"17","author":"Vivancos S\u00e1nchez","year":"2025","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.prp.2026.156471_bib48","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s42256-024-00868-w","article-title":"A transformer-based weakly supervised computational pathology method for clinical-grade diagnosis and molecular marker discovery of gliomas","volume":"6","author":"Jiang","year":"2024","journal-title":"Nat. Mach. Intell."},{"issue":"12","key":"10.1016\/j.prp.2026.156471_bib49","article-title":"A practical approach to the differential diagnosis of intracranial tumors: gross, histology, and immunoprofile-based algorithm","volume":"11","author":"Stoyanov","year":"2019","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib50","first-page":"1","article-title":"Pathological spectrum in recurrences of glioblastoma multiforme","volume":"107","author":"Marucci","year":"2015","journal-title":"Pathologica"},{"issue":"3","key":"10.1016\/j.prp.2026.156471_bib51","first-page":"500","article-title":"Analysis of the prognosis of high-grade gliomas in the view of new immunohistochemistry markers and 2016 WHO classification","volume":"32","author":"Dolen","year":"2022","journal-title":"Turk. Neurosurg."},{"issue":"10","key":"10.1016\/j.prp.2026.156471_bib52","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"33","key":"10.1016\/j.prp.2026.156471_bib53","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.2217\/fon-2021-0435","article-title":"Guideline conformity to the stupp regimen in patients with newly diagnosed glioblastoma multiforme in China","volume":"17","author":"Wang","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.prp.2026.156471_bib54","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3389\/fonc.2020.00840","article-title":"Real-world evidence in glioblastoma: Stupp's Regimen after a decade","volume":"10","author":"Lakomy","year":"2020","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3171\/2011.2.JNS10998","article-title":"An extent of resection threshold for newly diagnosed glioblastomas","volume":"115","author":"Sanai","year":"2011","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.prp.2026.156471_bib56","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3389\/fonc.2020.574012","article-title":"A review of newly diagnosed glioblastoma","volume":"10","author":"Oronsky","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib57","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1038\/s41598-020-61701-z","article-title":"Optimal timing of radiotherapy following gross total or subtotal resection of glioblastoma: a real-world assessment using the national cancer database","volume":"10","author":"Buszek","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib58","article-title":"State of the neoadjuvant therapy for glioblastoma multiforme\u2014where do we stand?","volume":"6","author":"Nabian","year":"2024","journal-title":"Neuro-Oncol. Adv."},{"issue":"3","key":"10.1016\/j.prp.2026.156471_bib59","doi-asserted-by":"crossref","first-page":"CNS60","DOI":"10.2217\/cns-2020-0010","article-title":"Can 3D-CRT meet the desired dose distribution to target and OARs in glioblastoma? A tertiary cancer center experience","volume":"9","author":"Kumar","year":"2020","journal-title":"CNS Oncol."},{"issue":"4","key":"10.1016\/j.prp.2026.156471_bib60","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/OP.22.00476","article-title":"Key clinical principles in the management of glioblastoma","volume":"19","author":"Kotecha","year":"2023","journal-title":"JCO Oncol. Pract."},{"issue":"12","key":"10.1016\/j.prp.2026.156471_bib61","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/cncr.34192","article-title":"Accelerated hypofractionated radiation for elderly or frail patients with a newly diagnosed glioblastoma: a pooled analysis of patient-level data from 4 prospective trials","volume":"128","author":"Perlow","year":"2022","journal-title":"Cancer"},{"issue":"35","key":"10.1016\/j.prp.2026.156471_bib62","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1200\/JCO.2015.62.6606","article-title":"International atomic energy agency randomized phase III study of radiation therapy in elderly and\/or frail patients with newly diagnosed glioblastoma multiforme","volume":"33","author":"Roa","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.prp.2026.156471_bib63","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.3390\/curroncol31070296","article-title":"Temozolomide (TMZ) in the treatment of glioblastoma multiforme\u2014a literature review and clinical outcomes","volume":"31","author":"Jezierza\u0144ski","year":"2024","journal-title":"Curr. Oncol."},{"issue":"8","key":"10.1016\/j.prp.2026.156471_bib64","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/neuonc\/nox025","article-title":"Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG oncology\/RTOG","volume":"19","author":"Blumenthal","year":"2017","journal-title":"Neuro-Oncology"},{"issue":"12","key":"10.1016\/j.prp.2026.156471_bib65","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/neuonc\/noaa107","article-title":"A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)","volume":"22","author":"Balana","year":"2020","journal-title":"Neuro-Oncology"},{"key":"10.1016\/j.prp.2026.156471_bib66","doi-asserted-by":"crossref","DOI":"10.33448\/rsd-v11i15.37205","article-title":"Quality of life in glioblastoma after the introduction of temozolomide: a systematic review","volume":"11","author":"Dias","year":"2022","journal-title":"Res. Soc. Dev."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib67","first-page":"17","article-title":"Mechanisms of temozolomide resistance in glioblastoma-a comprehensive review","volume":"4","author":"Singh","year":"2021","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.prp.2026.156471_bib68","doi-asserted-by":"crossref","first-page":"173","DOI":"10.7887\/jcns.29.173","article-title":"Surgical treatment of glioblastoma: current limitations and future possibilities","volume":"29","author":"Mukasa","year":"2020","journal-title":"Jpn. J. Neurosurg."},{"issue":"3","key":"10.1016\/j.prp.2026.156471_bib69","doi-asserted-by":"crossref","DOI":"10.3390\/jpm15030096","article-title":"Precision surgery for glioblastomas","volume":"15","author":"Price","year":"2025","journal-title":"J. Pers. Med"},{"issue":"5","key":"10.1016\/j.prp.2026.156471_bib70","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/nop\/npac019","article-title":"Safe surgery for glioblastoma: Recent advances and modern challenges","volume":"9","author":"Gerritsen","year":"2022","journal-title":"Neuro-Oncol. Pract."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib71","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","article-title":"Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy","volume":"16","author":"Zafar","year":"2025","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib72","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3171\/2008.4.17536","article-title":"Independent association of extent of resection with survival in patients with malignant brain astrocytoma","volume":"110","author":"McGirt","year":"2009","journal-title":"J. Neurosurg."},{"issue":"6","key":"10.1016\/j.prp.2026.156471_bib73","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/neuros\/nyab345","article-title":"Is There a role for surgical resection of multifocal glioblastoma? A retrospective analysis of 100 patients","volume":"89","author":"Friso","year":"2021","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/j.prp.2026.156471_bib74","doi-asserted-by":"crossref","DOI":"10.1111\/acel.14066","article-title":"Glioblastoma and its treatment are associated with extensive accelerated brain aging","volume":"23","author":"Ainslie","year":"2024","journal-title":"Aging Cell"},{"issue":"9","key":"10.1016\/j.prp.2026.156471_bib75","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.3390\/biomedicines13092136","article-title":"Radiotherapy in glioblastoma multiforme: evolution, limitations, and molecularly guided future","volume":"13","author":"Fern\u00e1ndez","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib76","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2176\/nmc.ra.2014-0188","article-title":"Pathophysiology, diagnosis, and treatment of radiation necrosis in the brain","volume":"55","author":"Miyatake","year":"2015","journal-title":"Neurol. Med Chir."},{"key":"10.1016\/j.prp.2026.156471_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1441460","article-title":"Challenges and advances in glioblastoma targeted therapy: the promise of drug repurposing and biomarker exploration","volume":"14","author":"Bae","year":"2024","journal-title":"Front Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib78","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood-brain barrier and blood-tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib79","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1038\/s41467-023-41694-9","article-title":"Breaking barriers for glioblastoma with a path to enhanced drug delivery","volume":"14","author":"Noorani","year":"2023","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.prp.2026.156471_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/genes12030445","article-title":"Decipher the glioblastoma microenvironment: the first milestone for new groundbreaking therapeutic strategies","volume":"12","author":"Fanelli","year":"2021","journal-title":"Genes"},{"key":"10.1016\/j.prp.2026.156471_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2021.106735","article-title":"Surgical outcome and molecular pattern characterization of recurrent glioblastoma multiforme: a single-center retrospective series","volume":"207","author":"Montemurro","year":"2021","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"5","key":"10.1016\/j.prp.2026.156471_bib82","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.ijrobp.2021.12.152","article-title":"The impact of tumor treating fields on glioblastoma progression patterns","volume":"112","author":"Glas","year":"2022","journal-title":"Int. J. Radiat. Oncol. * Biol. * Phys."},{"issue":"4","key":"10.1016\/j.prp.2026.156471_bib83","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","article-title":"Tumour treating fields therapy for glioblastoma: current advances and future directions","volume":"124","author":"Rominiyi","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"11","key":"10.1016\/j.prp.2026.156471_bib84","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3390\/brainsci13111536","article-title":"Advances in glioblastoma therapy: an update on current approaches","volume":"13","author":"Angom","year":"2023","journal-title":"Brain Sci."},{"issue":"14","key":"10.1016\/j.prp.2026.156471_bib85","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/j.ejca.2012.04.011","article-title":"NovoTTF-100A versus physician\u2019s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality","volume":"48","author":"Stupp","year":"2012","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-023-04348-w","article-title":"Association of tumor treating fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis","volume":"164","author":"Ballo","year":"2023","journal-title":"J. Neuro-Oncol."},{"issue":"11","key":"10.1016\/j.prp.2026.156471_bib87","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1109\/TBME.2025.3565520","article-title":"Potential of ultrashort pulsed electric fields to disrupt dense structure in glioma tumors","volume":"72","author":"Qian","year":"2025","journal-title":"IEEE Trans. Biomed. Eng."},{"issue":"5","key":"10.1016\/j.prp.2026.156471_bib88","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2055417","article-title":"Immunotherapy of glioblastoma: Recent advances and future prospects","volume":"18","author":"Yuan","year":"2022","journal-title":"Hum. Vaccin. Immunother."},{"issue":"3","key":"10.1016\/j.prp.2026.156471_bib89","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"13","key":"10.1016\/j.prp.2026.156471_bib90","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.3390\/ijms25137174","article-title":"CAR-T cells therapy in glioblastoma: a systematic review on molecular targets and treatment strategies","volume":"25","author":"Agosti","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.prp.2026.156471_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.797440","article-title":"Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions","volume":"10","author":"Alnefaie","year":"2022","journal-title":"Front Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib92","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.prp.2026.156471_bib93","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2024.13171","article-title":"CAR\u2011T cell therapy: a breakthrough in traditional cancer treatment strategies (Review)","volume":"29","author":"Sun","year":"2024","journal-title":"Mol. Med Rep."},{"issue":"399","key":"10.1016\/j.prp.2026.156471_bib94","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O'Rourke","year":"2017","journal-title":"Sci. Transl. Med"},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib95","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41698-024-00753-0","article-title":"CAR-T cell therapy for the treatment of adult high-grade gliomas","volume":"8","author":"Park","year":"2024","journal-title":"npj Precis. Oncol."},{"issue":"6","key":"10.1016\/j.prp.2026.156471_bib96","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.ymthe.2025.03.004","article-title":"CAR T cell therapy for glioblastoma: a review of the first decade of clinical trials","volume":"33","author":"Begley","year":"2025","journal-title":"Mol. Ther."},{"key":"10.1016\/j.prp.2026.156471_bib97","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.2147\/IJGM.S418837","article-title":"Insight into the progress in CAR-T cell therapy and combination with other therapies for glioblastoma","author":"Liang","year":"2023","journal-title":"Int. J. Gen. Med."},{"issue":"7","key":"10.1016\/j.prp.2026.156471_bib98","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1007\/s12094-024-03395-7","article-title":"Current approaches in glioblastoma multiforme immunotherapy","volume":"26","author":"Aghajani","year":"2024","journal-title":"Clin. Transl. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib99","article-title":"Advances in immunotherapy for glioblastoma multiforme","volume":"2017","author":"Huang","year":"2017","journal-title":"J. Immunol. Res."},{"issue":"2","key":"10.1016\/j.prp.2026.156471_bib100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.36401\/JIPO-23-34","article-title":"Immune checkpoint inhibitors and glioblastoma: a review on current state and future directions","volume":"7","author":"Ser","year":"2024","journal-title":"J. Immunother. Precis Oncol."},{"key":"10.1016\/j.prp.2026.156471_bib101","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fimmu.2024.1424396","article-title":"Immune checkpoint pathways in glioblastoma: a diverse and evolving landscape","volume":"15","author":"Inocencio","year":"2024","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.prp.2026.156471_bib102","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.prp.2026.156471_bib103","first-page":"2025","article-title":"An update on the clinical trial research of immunotherapy for glioblastoma","volume":"16","author":"Zhou","year":"2025","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.prp.2026.156471_bib104","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs bevacizumab in patients with recurrent glioblastoma: the CheckMate 143 phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1093\/neuonc\/noac099","article-title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial","volume":"25","author":"Omuro","year":"2023","journal-title":"Neuro-Oncology"},{"issue":"11","key":"10.1016\/j.prp.2026.156471_bib106","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1093\/neuonc\/noac116","article-title":"Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter","volume":"24","author":"Lim","year":"2022","journal-title":"Neuro-Oncology"},{"issue":"27","key":"10.1016\/j.prp.2026.156471_bib107","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO-25-00618","article-title":"Dual immune check point blockade in MGMT-unmethylated newly diagnosed glioblastoma: NRG oncology BN007, a randomized phase II\/III clinical trial","volume":"43","author":"Lassman","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.prp.2026.156471_bib108","doi-asserted-by":"crossref","first-page":"97","DOI":"10.36401\/JIPO-23-34","article-title":"Immune checkpoint inhibitors and glioblastoma: a review on current state and future directions","volume":"7","author":"Ser","year":"2024","journal-title":"J. Immunother. Precis. Oncol."},{"key":"10.1016\/j.prp.2026.156471_bib109","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1588081","article-title":"Harnessing immunotherapy: cancer vaccines as novel therapeutic strategies for brain tumor","volume":"16","author":"Kiel","year":"2025","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.prp.2026.156471_bib110","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1002\/cam4.5511","article-title":"Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions","volume":"12","author":"Zhou","year":"2023","journal-title":"Cancer Med."},{"issue":"6","key":"10.1016\/j.prp.2026.156471_bib111","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41423-020-0465-0","article-title":"Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses","volume":"17","author":"Hilligan","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.prp.2026.156471_bib112","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.672508","article-title":"Making a cold tumor hot: the role of vaccines in the treatment of glioblastoma","volume":"11","author":"Frederico","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib113","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma: a phase 3 prospective externally controlled cohort trial","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib114","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12967-018-1507-6","article-title":"First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma","volume":"16","author":"Liau","year":"2018","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib115","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s44178-022-00021-w","article-title":"Peptide vaccine against glioblastoma: from bench to bedside","volume":"1","author":"Yang","year":"2022","journal-title":"Holist. Integr. Oncol."},{"key":"10.1016\/j.prp.2026.156471_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104963","article-title":"Glioblastoma vaccines: past, present, and opportunities","volume":"100","author":"Xiong","year":"2024","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib117","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13041-025-01221-x","article-title":"Recent developments in peptide vaccines against Glioblastoma, a review and update","volume":"18","author":"Salahlou","year":"2025","journal-title":"Mol. Brain"},{"issue":"6","key":"10.1016\/j.prp.2026.156471_bib118","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/neuonc\/nou348","article-title":"A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study","volume":"17","author":"Schuster","year":"2015","journal-title":"Neuro-Oncology"},{"issue":"7","key":"10.1016\/j.prp.2026.156471_bib119","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1200\/JCO.22.00996","article-title":"Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma","volume":"41","author":"Ahluwalia","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.prp.2026.156471_bib120","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.71187","article-title":"Promising cancer vaccine for glioblastoma therapy: a focus on mRNA vaccine","volume":"14","author":"Barati","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.prp.2026.156471_bib121","doi-asserted-by":"crossref","first-page":"436","DOI":"10.3389\/fonc.2019.00436","article-title":"STAT3 contributes to oncolytic newcastle disease virus-induced immunogenic cell death in melanoma cells","volume":"9","author":"Shao","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.prp.2026.156471_bib122","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fimmu.2023.1118246","article-title":"Oncolytic immunovirotherapy for high-grade gliomas: a novel and an evolving therapeutic option","volume":"14","author":"Asija","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.prp.2026.156471_bib123","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.2147\/CMAR.S528875","article-title":"Optimizing oncolytic virotherapy for malignant glioma: from bench to bedside","author":"Jiang","year":"2025","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.prp.2026.156471_bib124","unstructured":"A Phase I\/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII. 2011."},{"key":"10.1016\/j.prp.2026.156471_bib125","unstructured":"Phase I\/IIa Study of Intratumoral\/Intracerebral or Intravenous\/Intracerebral Administration of Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme. 2011."},{"key":"10.1016\/j.prp.2026.156471_bib126","unstructured":"Phase I Trial of Combination of DNX-2401 (Formerly Named Delta-24-RGD) Oncolytic Adenovirus With a Short Course of Temozolomide for Treatment of Glioblastoma at First Recurrent, I. Dnatrix, Editor. 2013."},{"key":"10.1016\/j.prp.2026.156471_bib127","unstructured":"Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma. 2024."},{"key":"10.1016\/j.prp.2026.156471_bib128","unstructured":"ATTAC-II: A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-Pulsed Dendritic Cells With Tetanus-Diphtheria Toxoid Vaccine in Patients With Newly-Diagnosed Glioblastoma, I. National Cancer, Editor. 2015."},{"issue":"2","key":"10.1016\/j.prp.2026.156471_bib129","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1208\/s12249-021-01928-9","article-title":"Enhancement of therapies for glioblastoma (GBM) using nanoparticle-based delivery systems","volume":"22","author":"Wiwatchaitawee","year":"2021","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib130","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/cancers12010242","article-title":"Nano-therapies for glioblastoma treatment","volume":"12","author":"Alphand\u00e9ry","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2026.156471_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.141998","article-title":"Matrix metallopeptidase 2-responsive curcumin-loaded nanoparticles-induced signal transducer and activator of transcription 3 inhibition suppresses glioblastoma multiforme growth via enhancing nuclear factor erythroid 2-related factor 2 activity","volume":"307","author":"Jia","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.prp.2026.156471_bib132","article-title":"Innovative nanoparticle-based therapeutic strategies against glioblastoma multiform: a focus on enhanced delivery systems and efficacy","volume":"13","author":"Wang","year":"2025","journal-title":"Front Bioeng. Biotechnol."},{"key":"10.1016\/j.prp.2026.156471_bib133","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2017.06.028","article-title":"Liposomal temozolomide drug delivery using convection enhanced delivery","volume":"261","author":"Nordling-David","year":"2017","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.prp.2026.156471_bib134","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3390\/pharmaceutics14020308","article-title":"Liposomal-based formulations: a path from basic research to temozolomide delivery inside glioblastoma tissue","volume":"14","author":"Amarandi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.prp.2026.156471_bib135","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2023.102704","article-title":"Microfluidic-derived docosahexaenoic acid liposomes for glioblastoma therapy","volume":"53","author":"Mendanha","year":"2023","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"issue":"3","key":"10.1016\/j.prp.2026.156471_bib136","doi-asserted-by":"crossref","first-page":"512","DOI":"10.34172\/apb.2023.062","article-title":"Drug delivery of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) to target brain tumors","volume":"13","author":"Mehrdadi","year":"2022","journal-title":"Adv. Pharm. Bull."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib137","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40005-021-00548-6","article-title":"Multifunctional lipidic nanocarriers for effective therapy of glioblastoma: recent advances in stimuli-responsive, receptor and subcellular targeted approaches","volume":"52","author":"Hegde","year":"2022","journal-title":"J. Pharm. Investig."},{"issue":"6","key":"10.1016\/j.prp.2026.156471_bib138","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2217\/nnm-2018-0436","article-title":"Nutlin-loaded magnetic solid lipid nanoparticles for targeted glioblastoma treatment","volume":"14","author":"Grillone","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.prp.2026.156471_bib139","article-title":"Lipid nanoparticles for the treatment of glioblastoma multiforme: current status of research and clinical translation","volume":"108","author":"Kulkarni","year":"2025","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.prp.2026.156471_bib140","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jconrel.2020.02.020","article-title":"Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting","volume":"321","author":"Agrawal","year":"2020","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib141","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s43094-022-00414-8","article-title":"Nanostructured lipid carriers: a promising drug carrier for targeting brain tumours","volume":"8","author":"Garg","year":"2022","journal-title":"Future J. Pharm. Sci."},{"key":"10.1016\/j.prp.2026.156471_bib142","doi-asserted-by":"crossref","first-page":"3039","DOI":"10.2147\/IJN.S161163","article-title":"Lactoferrin- and RGD-comodified, temozolomide and vincristine-coloaded nanostructured lipid carriers for gliomatosis cerebri combination therapy","volume":"13","author":"Zhang","year":"2018","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.prp.2026.156471_bib143","article-title":"Applications of polymeric nanoparticles in drug delivery for glioblastoma","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharm."},{"key":"10.1016\/j.prp.2026.156471_bib144","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jconrel.2021.02.016","article-title":"Polymeric micelles in cancer therapy: state of the art","volume":"332","author":"Ghosh","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.prp.2026.156471_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2021.112261","article-title":"Multifunctional silica-coated mixed polymeric micelles for integrin-targeted therapy of pediatric patient-derived glioblastoma","volume":"128","author":"Chauhan","year":"2021","journal-title":"Materials Science Engineering C"},{"issue":"4","key":"10.1016\/j.prp.2026.156471_bib146","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3390\/cancers15041075","article-title":"Dendrimer technology in glioma: functional design and potential applications","volume":"15","author":"Gaitsch","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.prp.2026.156471_bib147","doi-asserted-by":"crossref","unstructured":"Panchpuri, M., et al., Chapter 14 - Dendrimer-assisted nanotechnological ways for glioblastoma drug delivery, in Emerging Paradigms in Delivery of Therapeutic Agents for the Treatment of Glioblastoma, R. Sharma, et al., Editors. 2026, Academic Press. p. 299-316.","DOI":"10.1016\/B978-0-443-33319-4.00011-2"},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib148","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s42269-025-01309-3","article-title":"Development of Angiopep-2 targeted dendrimer-based nanotheranostic system for enhanced temozolomide delivery to glioblastoma multiforme","volume":"49","author":"Parashar","year":"2025","journal-title":"Bull. Natl. Res. Cent."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib149","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/micro5010002","article-title":"Lipidic and inorganic nanoparticles for targeted glioblastoma multiforme therapy: advances and strategies","volume":"5","author":"Musielak","year":"2025","journal-title":"Micro"},{"key":"10.1016\/j.prp.2026.156471_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112951","article-title":"Biomedical applications of metallic nanoparticles in cancer: Current status and future perspectives","volume":"150","author":"Khursheed","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.prp.2026.156471_bib151","doi-asserted-by":"crossref","first-page":"9327","DOI":"10.2147\/IJN.S525462","article-title":"Effect of photothermal therapy using gold nanoparticles conjugated with hyaluronic acid in an intracranial murine glioblastoma model","author":"Domingo-Diez","year":"2025","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10971-022-05983-x","article-title":"An extensive review on mesoporous silica from inexpensive resources: properties, synthesis, and application toward modern technologies","volume":"105","author":"Saravanan","year":"2023","journal-title":"J. Sol. -Gel Sci. Technol."},{"issue":"17","key":"10.1016\/j.prp.2026.156471_bib153","doi-asserted-by":"crossref","first-page":"21722","DOI":"10.1021\/acsami.4c04289","article-title":"Overcoming the blood\u2013brain tumor barrier with docetaxel-loaded mesoporous silica nanoparticles for treatment of temozolomide-resistant glioblastoma","volume":"16","author":"Hsu","year":"2024","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib154","doi-asserted-by":"crossref","first-page":"14283","DOI":"10.1038\/s41598-025-97943-y","article-title":"Enhanced detection of glioblastoma vasculature with superparamagnetic iron oxide nanoparticles and MRI","volume":"15","author":"Janowicz","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.prp.2026.156471_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.126151","article-title":"Beta-cyclodextrin decorated hyaluronic acid-coated SPIONs for improved delivery of temozolomide","volume":"684","author":"Kasprzyk","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"12","key":"10.1016\/j.prp.2026.156471_bib156","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1080\/17435889.2025.2503694","article-title":"Recent advances in nanomaterial-based brain-targeted delivery systems for glioblastoma therapy","volume":"20","author":"Qu","year":"2025","journal-title":"Nanomedicine"},{"key":"10.1016\/j.prp.2026.156471_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.114426","article-title":"Clinical translation of nanomedicines for brain diseases: current challenges and future directions","volume":"389","author":"Wang","year":"2026","journal-title":"J. Control. Release"},{"key":"10.1016\/j.prp.2026.156471_bib158","doi-asserted-by":"crossref","first-page":"9597","DOI":"10.2147\/IJN.S531451","article-title":"Advances and challenges in nano-delivery systems for glioblastoma treatment: a comprehensive review","volume":"20","author":"Wang","year":"2025","journal-title":"Int J. Nanomed."},{"key":"10.1016\/j.prp.2026.156471_bib159","doi-asserted-by":"crossref","unstructured":"Visht, S., et al., Chapter 8 - Herbal approaches for the treatment of glioblastoma, in Emerging Paradigms in Delivery of Therapeutic Agents for the Treatment of Glioblastoma, R. Sharma, et al., Editors. 2026, Academic Press. p. 181-202.","DOI":"10.1016\/B978-0-443-33319-4.00008-2"},{"issue":"10","key":"10.1016\/j.prp.2026.156471_bib160","doi-asserted-by":"crossref","DOI":"10.3390\/molecules30102108","article-title":"Curcumin-induced molecular mechanisms in U-87 MG glioblastoma cells: insights from global gene expression profiling","volume":"30","author":"Mashozhera","year":"2025","journal-title":"Molecules"},{"issue":"11","key":"10.1016\/j.prp.2026.156471_bib161","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9111562","article-title":"Curcumin and radiotherapy exert synergistic anti-glioma effect in vitro","volume":"9","author":"Zoi","year":"2021","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.prp.2026.156471_bib162","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s00432-024-05625-5","article-title":"Resveratrol ameliorates glioblastoma inflammatory response by reducing NLRP3 inflammasome activation through inhibition of the JAK2\/STAT3 pathway","volume":"150","author":"Zhang","year":"2024","journal-title":"J. Cancer Res Clin. Oncol."},{"issue":"11","key":"10.1016\/j.prp.2026.156471_bib163","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24119453","article-title":"Resveratrol enhances temozolomide efficacy in glioblastoma cells through downregulated MGMT and negative regulators-related STAT3 inactivation","volume":"24","author":"Wu","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.prp.2026.156471_bib164","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20193314","article-title":"Dihydroartemisinin initiates ferroptosis in glioblastoma through GPX4 inhibition","volume":"40","author":"Yi","year":"2020","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib165","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3892\/ol.2015.3183","article-title":"Dihydroartemisinin increases temozolomide efficacy in glioma cells by inducing autophagy","volume":"10","author":"Zhang","year":"2015","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.prp.2026.156471_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2021.153483","article-title":"Ginsenoside F2 induces cellular toxicity to glioblastoma through the impairment of mitochondrial function","volume":"83","author":"Kim","year":"2021","journal-title":"Phytomedicine"},{"issue":"3","key":"10.1016\/j.prp.2026.156471_bib167","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci15030325","article-title":"Naringenin exhibits antiglioma activity related to Aryl hydrocarbon receptor activity and IL-6, CCL2, and TNF-\u03b1 expression","volume":"15","author":"Santana","year":"2025","journal-title":"Brain Sci."},{"issue":"11","key":"10.1016\/j.prp.2026.156471_bib168","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.31557\/APJCP.2021.22.11.3607","article-title":"Opuntiol inhibits growth and induces apoptosis in human glioblastoma cells by upregulating active caspase 3 expression","volume":"22","author":"Ashfaque","year":"2021","journal-title":"Asian Pac. J. Cancer Prevent. APJCP"},{"issue":"19","key":"10.1016\/j.prp.2026.156471_bib169","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.3390\/cancers17193197","article-title":"Quercetin increases expression of membrane-TRAIL in glioblastoma cells resulting in apoptosis","volume":"17","author":"Thorpe","year":"2025","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib170","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.12706","article-title":"Withaferin A triggers G2\/M arrest and intrinsic apoptosis in glioblastoma cells via ATF4-ATF3-CHOP axis","volume":"53","author":"Tang","year":"2020","journal-title":"Cell Prolif."},{"key":"10.1016\/j.prp.2026.156471_bib171","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.2147\/DDDT.S422512","article-title":"Withaferin A: a dietary supplement with promising potential as an anti-tumor therapeutic for cancer treatment-pharmacology and mechanisms","author":"Xing","year":"2023","journal-title":"Drug Des. Dev. Ther."},{"issue":"10","key":"10.1016\/j.prp.2026.156471_bib172","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1007\/s11064-020-03093-0","article-title":"Diosgenin as a novel alternative therapy for inhibition of growth, invasion, and angiogenesis abilities of different glioblastoma cell lines","volume":"45","author":"Khathayer","year":"2020","journal-title":"Neurochem. Res"},{"issue":"10","key":"10.1016\/j.prp.2026.156471_bib173","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1021\/acs.jnatprod.0c00580","article-title":"Cedrol, a sesquiterpene alcohol, enhances the anticancer efficacy of temozolomide in attenuating drug resistance via regulation of the DNA damage response and MGMT expression","volume":"83","author":"Chang","year":"2020","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.prp.2026.156471_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2024.155635","article-title":"Curcumin-primed olfactory mucosa-derived mesenchymal stem cells mitigate cerebral ischemia\/reperfusion injury-induced neuronal PANoptosis by modulating microglial polarization","volume":"129","author":"Lan","year":"2024","journal-title":"Phytomedicine"},{"issue":"4","key":"10.1016\/j.prp.2026.156471_bib175","doi-asserted-by":"crossref","DOI":"10.14744\/ejmo.2023.32728","article-title":"Didymin exhibits different cytotoxicity patterns on U-87 MG human glioblastoma cells and orchestrates the release of substance P (SP) and interleukin-6 (IL-6) in a time depending manner.","volume":"7","author":"Bulut","year":"2023","journal-title":"EJMO"},{"issue":"1","key":"10.1016\/j.prp.2026.156471_bib176","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41420-024-02009-z","article-title":"PLC\u03b21 by-passes early growth response -1 to induce the differentiation of neuronal cells","volume":"10","author":"Gonz\u00e1lez-Burguera","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.prp.2026.156471_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2020.100771","article-title":"Location-dependent role of phospholipase C signaling in the brain: physiology and pathology","volume":"79","author":"Rusciano","year":"2021","journal-title":"Adv. Biol. Regul."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S034403382600124X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S034403382600124X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:36:39Z","timestamp":1785508599000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S034403382600124X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":177,"alternative-id":["S034403382600124X"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156471","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glioblastoma IDH-wildtype: An integrative review of pathophysiological mechanisms, diagnostic innovations, and emerging therapeutic modalities","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156471","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier GmbH. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"156471"}}